Henry Schein Completes Acquisition of Acentus
Henry Schein (Nasdaq: HSIC) has completed the acquisition of Acentus, a Tampa-based national medical supplier specializing in Continuous Glucose Monitors (CGMs) with annual revenue of approximately $35 million. The transaction is expected to be neutral to 2025 non-GAAP earnings per share and accretive thereafter.
This acquisition follows Henry Schein's previous acquisitions of Prism Medical Products (2021), Shield Healthcare, and Mini Pharmacy (2023), strengthening its position in the homecare medical supplies market. With the addition of Acentus, Henry Schein's homecare medical products platform will now have an annual revenue base exceeding $350 million.
The four Acentus founders will join Henry Schein, bringing their expertise in the product category and healthcare industry. The acquisition aims to enhance Henry Schein's ability to serve customers through direct CGM product delivery to patients' homes.
Henry Schein (Nasdaq: HSIC) ha completato l'acquisizione di Acentus, un fornitore nazionale di prodotti medici con sede a Tampa, specializzato in Monitoraggio Continuo della Glucosio (CGM) con un fatturato annuale di circa 35 milioni di dollari. Si prevede che la transazione sia neutra per gli utili per azione non-GAAP del 2025 e accrescitiva in seguito.
Questa acquisizione segue quelle precedenti di Henry Schein, tra cui Prism Medical Products (2021), Shield Healthcare e Mini Pharmacy (2023), rafforzando la sua posizione nel mercato delle forniture mediche per la cura domiciliare. Con l'aggiunta di Acentus, la piattaforma di prodotti medici per la cura domiciliare di Henry Schein avrà ora una base di fatturato annuo superiore ai 350 milioni di dollari.
I quattro fondatori di Acentus entreranno in Henry Schein, portando la loro esperienza nel settore dei prodotti e dell'assistenza sanitaria. L'acquisizione mira a migliorare la capacità di Henry Schein di servire i clienti attraverso la consegna diretta dei prodotti CGM a casa dei pazienti.
Henry Schein (Nasdaq: HSIC) ha completado la adquisición de Acentus, un proveedor nacional de productos médicos con sede en Tampa, especializado en Monitores Continuos de Glucosa (CGM) con ingresos anuales de aproximadamente $35 millones. Se espera que la transacción sea neutral para las ganancias por acción no-GAAP de 2025 y accretiva posteriormente.
Esta adquisición sigue a las anteriores de Henry Schein de Prism Medical Products (2021), Shield Healthcare y Mini Pharmacy (2023), fortaleciendo su posición en el mercado de suministros médicos para el cuidado en el hogar. Con la adición de Acentus, la plataforma de productos médicos para el hogar de Henry Schein ahora tendrá una base de ingresos anuales que supera los $350 millones.
Los cuatro fundadores de Acentus se unirán a Henry Schein, aportando su experiencia en la categoría de productos y en la industria de la salud. La adquisición tiene como objetivo mejorar la capacidad de Henry Schein para atender a los clientes a través de la entrega directa de productos CGM a las casas de los pacientes.
헨리 샤인 (Nasdaq: HSIC)이 연간 수익 약 3,500만 달러의 지속적 혈당 모니터(CGM)를 전문으로 하는 플로리다주 탬파에 본사를 둔 국가 의약품 공급업체인 Acentus를 인수 완료했습니다. 이번 거래는 2025년 비-GAAP 주당 순이익에는 중립적일 것으로 예상되며 그 이후에는 수익을 증가시킬 것으로 보입니다.
이번 인수는 헨리 샤인이 Prism Medical Products (2021), Shield Healthcare 및 Mini Pharmacy (2023)를 인수한 이후 이뤄지며, 자택 의료 용품 시장에서의 입지를 강화하고 있습니다. Acentus의 추가로 헨리 샤인의 홈케어 의료 제품 플랫폼은 이제 연간 수익 기반이 3억 5천만 달러를 초과하게 됩니다.
Acentus의 네 명의 창립자는 헨리 샤인에 합류하여 제품 카테고리 및 의료 산업에서의 전문 지식을 가져올 것입니다. 이번 인수의 목표는 헨리 샤인이 고객에게 CGM 제품을 환자의 집으로 직접 배송하여 서비스를 향상시키는 것입니다.
Henry Schein (Nasdaq: HSIC) a finalisé l'acquisition de Acentus, un fournisseur national de matériel médical basé à Tampa, spécialisé dans les Moniteurs Glucose Continus (CGM) avec un chiffre d'affaires annuel d'environ 35 millions de dollars. La transaction devrait être neutre pour les bénéfices par action non-GAAP de 2025 et accretive par la suite.
Cette acquisition fait suite aux acquisitions précédentes de Henry Schein, notamment Prism Medical Products (2021), Shield Healthcare et Mini Pharmacy (2023), renforçant ainsi sa position sur le marché des fournitures médicales à domicile. Avec l'ajout d'Acentus, la plateforme de produits médicaux à domicile de Henry Schein aura désormais une base de revenus annuels dépassant les 350 millions de dollars.
Les quatre fondateurs d'Acentus rejoindront Henry Schein, apportant leur expertise dans la catégorie de produits et l'industrie de la santé. L'acquisition vise à améliorer la capacité de Henry Schein à servir ses clients grâce à la livraison directe des produits CGM aux domiciles des patients.
Henry Schein (Nasdaq: HSIC) hat die Übernahme von Acentus abgeschlossen, einem nationalen medizinischen Zulieferer mit Sitz in Tampa, der sich auf kontinuierliche Glukosemonitore (CGMs) spezialisiert hat und jährlich etwa 35 Millionen Dollar Umsatz erzielt. Die Transaktion wird voraussichtlich neutral für die Non-GAAP-Gewinne pro Aktie im Jahr 2025 und danach gewinnbringend sein.
Diese Übernahme folgt den vorherigen Akquisitionen von Henry Schein: Prism Medical Products (2021), Shield Healthcare und Mini Pharmacy (2023), wodurch die Position im Markt für medizinische Versorgungen im häuslichen Bereich gestärkt wird. Mit der Hinzufügung von Acentus wird die Plattform für medizinische Produkte von Henry Schein für die häusliche Pflege nun einen Jahresumsatz von über 350 Millionen Dollar haben.
Die vier Gründer von Acentus werden zu Henry Schein stoßen und ihre Expertise in der Produktkategorie und im Gesundheitswesen einbringen. Die Übernahme zielt darauf ab, die Fähigkeit von Henry Schein zu verbessern, Kunden durch die direkte Lieferung von CGM-Produkten an die Wohnungen der Patienten zu bedienen.
- Expansion of homecare medical products platform to over $350M annual revenue base
- Strategic enhancement of CGM product delivery capabilities
- Acquisition expected to be accretive to earnings after 2025
- Integration of experienced Acentus founding team
- Neutral impact on 2025 non-GAAP earnings per share
Insights
The acquisition of Acentus marks a strategic expansion in Henry Schein's homecare solutions segment, particularly in the lucrative Continuous Glucose Monitoring market. With Acentus's
This acquisition follows a pattern of strategic consolidation in the homecare medical supplies market, building upon previous acquisitions of Prism Medical Products (2021), Shield Healthcare and Mini Pharmacy (2023). The CGM market is experiencing rapid growth due to increasing diabetes prevalence and the shift toward home healthcare monitoring. The retention of Acentus's founding team adds valuable expertise in specialized medical product distribution.
For investors, this represents a calculated move to capitalize on the growing home healthcare sector, with particular focus on high-margin, recurring revenue streams from CGM products. The integration risk appears manageable given HSIC's track record with similar acquisitions in this space.
The CGM market acquisition is particularly timely as the healthcare industry continues to shift toward home-based care solutions. CGMs represent a high-growth segment within medical devices, with a compound annual growth rate projected to exceed
By acquiring Acentus, Henry Schein strengthens its position in the direct-to-patient distribution model, which is becoming increasingly important in healthcare delivery. This move also positions them to benefit from the expanding Medicare coverage for CGM devices and the growing adoption of these devices among Type 2 diabetes patients, not just Type 1. The company's expanded homecare platform now offers a more comprehensive solution for healthcare providers and patients, potentially leading to increased market share and improved competitive positioning.
Henry Schein Home Solutions Business Expands with the Addition of Leading Supplier of Homecare Medical Products
Headquartered in
“Henry Schein continues to expand upon our national homecare solutions platform to effectively address the evolving needs of our customers, which includes clinics, physician practices, health systems, and patients receiving care at home,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein. “The acquisition of Acentus represents an important step towards strengthening our position within the home medical supply market. By directly delivering CGM products to patients’ homes, we are enhancing our ability to serve our valued customers and drive growth.”
The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and Mini Pharmacy in 2023, reinforcing the Company’s strategic commitment to the homecare medical supplies market. Henry Schein’s homecare medical products platform will now have an annual revenue base in excess of
Acentus Founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia will join Henry Schein and bring their expertise and experience in the product category and the health care industry.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 26,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in
For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. A fuller discussion of our operations, financial condition, and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations. Forward looking statements include the overall impact of the Novel Coronavirus Disease 2019 (COVID-19) on the Company, its results of operations, liquidity and financial condition (including any estimates of the impact on these items), the rate and consistency with which dental and other practices resume or maintain normal operations in
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: risks associated with COVID-19 and any variants thereof, as well as other disease outbreaks, epidemics, pandemics, or similar wide-spread public health concerns and other natural disasters; our dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; legal, regulatory, compliance, cybersecurity, financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; the repeal or judicial prohibition on implementation of the Affordable Care Act; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global and domestic macroeconomic and political conditions, including inflation, deflation, recession, fluctuations in energy pricing and the value of the
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114760320/en/
Investors
Ronald N. South
Senior Vice President and Chief Financial Officer
ronald.south@henryschein.com
(631) 843-5500
Graham Stanley
Vice President, Investor Relations and Strategic Financial Project Officer
graham.stanley@henryschein.com
(631) 843-5500
Media
Ann Marie Gothard
Vice President, Global Corporate Media Relations
annmarie.gothard@henryschein.com
(631) 390-8169
Source: Henry Schein, Inc.
FAQ
What is the annual revenue of Acentus that HSIC acquired?
When will the Acentus acquisition become accretive to HSIC earnings?
What is the total revenue of HSIC's homecare medical products platform after the Acentus acquisition?
What recent acquisitions has HSIC made in the homecare medical supplies market?
What is Acentus's main product specialty that HSIC acquired?
